Free Trial
→ A grave, grave error. (From Porter & Company) (Ad) Buy BNTX Stock  Free BNTX Stock Alerts

BioNTech (BNTX) Financials

BioNTech logo
$97.53 -1.02 (-1.04%)
Closing price 04:00 PM Eastern
Extended Trading
$97.03 -0.50 (-0.51%)
As of 06:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for BioNTech

Annual Income Statements for BioNTech

This table shows BioNTech's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017
Net Income / (Loss) Attributable to Common Shareholders		 -689 1,029 10,093 11,649 19 -201 -55 -103
Consolidated Net Income / (Loss)		 -689 1,029 10,093 11,649 19 -201 -55 -103
Net Income / (Loss) Continuing Operations		 -689 1,029 10,093 11,649 19 -201 -55 -103
Total Pre-Tax Income 		-701 1,312 13,858 17,030 -178 -201 -55 -103
Total Operating Income		 -1,360 764 13,525 17,298 -101 -204 -62 -74
Total Gross Profit		 2,287 3,561 15,315 18,183 517 102 130 63
Total Revenue		 2,848 4,225 18,519 21,478 589 122 146 74
Operating Revenue		 2,848 4,225 18,519 21,478 589 122 146 74
Total Cost of Revenue		 560 663 3,204 3,295 72 20 16 11
Operating Cost of Revenue		 560 663 3,204 3,295 72 20 16 11
Total Operating Expenses		 3,648 2,797 1,790 884 617 305 192 136
Selling, General & Admin Expense		 550 548 515 313 115 51 30 28
Marketing Expense		 70 69 64 57 18 3.03 3.48 7.93
Research & Development Expense		 2,333 1,972 1,644 1,074 788 254 164 103
Other Operating Expenses / (Income)		 694 208 -434 -560 -303 -2.24 -5.35 -2.48
Total Other Income / (Expense), net		 659 548 333 -269 -77 2.36 7.09 -30
Interest Expense		 28 26 20 345 79 2.24 2.02 32
Interest & Investment Income		 687 575 353 77 1.95 4.60 9.21 2.56
Income Tax Expense		 -13 283 3,765 5,380 -197 -0.22 0.69 0.05
Basic Earnings per Share		 ($2.87) $4.28 $41.49 $42.18 $0.06 ($0.85) ($0.25) ($0.61)
Weighted Average Basic Shares Outstanding		 239.97M 237.73M 240.99M 246.81M 241.52B - - -
Diluted Earnings per Share		 ($2.87) $4.24 $40.41 $39.63 $0.06 ($0.85) ($0.25) ($0.61)
Weighted Average Diluted Shares Outstanding		 239.97M 237.73M 240.99M 246.81M 241.52B - - -
Weighted Average Basic & Diluted Shares Outstanding		 239.97M 237.73M 240.99M 246.81M 241.52B - - -

Quarterly Income Statements for BioNTech

No quarterly income statements for BioNTech are available.

Annual Cash Flow Statements for BioNTech

This table details how cash moves in and out of BioNTech's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017
Net Change in Cash & Equivalents		 809 6,313 13,033 473 900 121 275 -128
Net Cash From Operating Activities		 410 1,558 13,404 1,007 -16 -223 -67 -63
Net Cash From Continuing Operating Activities		 410 1,558 13,404 1,022 -16 -223 -67 -58
Net Income / (Loss) Continuing Operations		 -689 1,029 10,093 17,030 -178 -201 -55 -103
Consolidated Net Income / (Loss)		 -689 1,029 10,093 17,030 -178 -201 -55 -103
Depreciation Expense		 308 203 132 85 47 38 25 13
Non-Cash Adjustments To Reconcile Net Income		 4.76 194 3,088 -22 230 35 9.09 35
Changes in Operating Assets and Liabilities, net		 785 132 91 -16,071 -116 -94 -47 -2.44
Net Cash From Investing Activities		 401 5,572 50 -641 -177 -87 -76 -63
Net Cash From Continuing Investing Activities		 401 5,572 50 -622 -177 -87 -76 -23
Acquisitions		 0.00 -373 0.00 -24 -74 -6.85 0.00 0.00
Sale of Property, Plant & Equipment		 401 5,945 0.64 - 1.47 0.00 0.81 6.24
Net Cash From Financing Activities		 -2.38 -817 99 107 1,093 430 418 -1.97
Net Cash From Continuing Financing Activities		 -2.38 -817 99 107 1,093 430 418 -1.97
Repayment of Debt		 -2.38 -0.11 -20 -75 -17 -3.48 -2.46 -1.97
Repurchase of Preferred Equity		 0.00 -817 - 0.00 - - - -
Issuance of Debt		 0.00 0.33 0.86 0.00 191 12 6.41 0.00

Quarterly Cash Flow Statements for BioNTech

No quarterly cash flow statements for BioNTech are available.

Annual Balance Sheets for BioNTech

This table presents BioNTech's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Total Assets		 23,320 25,450 24,904 17,917 2,832 895 747
Total Current Assets		 19,464 21,601 23,452 17,059 2,036 629 514
Cash & Equivalents		 10,105 12,902 14,844 1,916 1,478 583 471
Accounts Receivable		 1,515 2,385 7,644 14,014 202 13 22
Inventories, net		 293 396 470 569 78 13 6.63
Current Deferred & Refundable Income Taxes		 52 198 0.43 0.45 1.10 0.85 1.02
Other Current Assets		 231 316 291 128 276 17 13
Other Current Nonoperating Assets		 7,268 5,404 203 432 - 1.89 0.38
Plant, Property, & Equipment, net		 968 838 652 365 277 104 76
Plant, Property & Equipment, gross		 968 838 652 365 277 104 76
Total Noncurrent Assets		 2,889 3,011 800 493 519 162 158
Goodwill		 394 401 65 - - - -
Intangible Assets		 818 889 170 229 200 100 101
Noncurrent Deferred & Refundable Income Taxes		 85 90 246 0.00 197 0.00 -
Other Noncurrent Operating Assets		 1,592 1,630 319 264 122 62 57
Total Liabilities & Shareholders' Equity		 23,320 25,450 24,904 17,917 2,832 895 747
Total Liabilities		 3,228 3,054 3,449 4,456 1,157 341 442
Total Current Liabilities		 2,612 2,290 3,157 3,940 740 155 144
Short-Term Debt		 1,494 459 840 - 11 5.96 9.46
Accounts Payable		 442 392 218 181 125 23 48
Current Deferred & Payable Income Tax Liabilities		 4.66 581 637 1,776 0.00 0.17 0.34
Other Current Liabilities		 671 858 1,461 1,984 604 126 87
Total Noncurrent Liabilities		 616 763 292 516 416 186 297
Long-Term Debt		 49 43 6.53 - 282 77 -
Capital Lease Obligations		 222 211 188 194 - - -
Noncurrent Deferred & Payable Income Tax Liabilities		 44 44 18 80 0.24 0.00 -
Other Noncurrent Operating Liabilities		 302 465 79 241 134 109 297
Total Equity & Noncontrolling Interests		 20,092 22,396 21,455 13,461 1,676 554 306
Total Preferred & Common Equity		 20,092 22,396 21,455 13,461 1,676 554 305
Total Common Equity		 20,092 22,396 21,455 13,461 1,676 554 305
Common Stock		 257 275 266 279 301 261 221
Retained Earnings		 19,768 21,862 20,148 11,185 -500 - -
Treasury Stock		 -8.90 -12 -5.67 -4.30 -5.86 -6.20 0.00
Other Equity Adjustments		 76 271 1,048 2,001 1,881 776 365

Quarterly Balance Sheets for BioNTech

No quarterly balance sheets for BioNTech are available.

Annual Metrics And Ratios for BioNTech

This table displays calculated financial ratios and metrics derived from BioNTech's official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017
Growth Metrics		 - - - - - - - -
Revenue Growth		 -32.59% -77.19% -13.78% 3,545.38% 383.42% -16.53% 97.33% 0.00%
EBITDA Growth		 -208.83% -92.92% -21.44% 32,662.70% 67.77% -352.93% 40.10% 0.00%
EBIT Growth		 -278.13% -94.35% -21.81% 17,284.74% 50.58% -229.96% 16.24% 0.00%
NOPAT Growth		 -258.98% -93.92% -16.75% 16,893.19% 50.58% -230.47% 16.26% 0.00%
Net Income Growth		 -166.92% -89.80% -13.36% 62,635.91% 109.23% -264.09% 46.50% 0.00%
EPS Growth		 -167.68% -89.51% 1.96% 65,950.00% 107.06% -240.00% 50.98% 0.00%
Operating Cash Flow Growth		 -73.70% -88.38% 1,231.12% 6,205.89% 92.60% -230.59% -6.72% 0.00%
Free Cash Flow Firm Growth		 -119.56% -76.37% 1,250.12% 299.73% -41.05% -394.99% 0.00% 0.00%
Invested Capital Growth		 -6.63% -35.48% -34.17% 2,204.34% 832.84% 131.81% 0.00% 0.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - -
Gross Margin		 80.32% 84.29% 82.70% 84.66% 87.70% 83.98% 89.27% 84.87%
EBITDA Margin		 -36.94% 22.88% 73.75% 80.94% -9.06% -135.91% -25.05% -82.51%
Operating Margin		 -47.77% 18.08% 73.03% 80.54% -17.08% -167.13% -42.21% -99.48%
EBIT Margin		 -47.77% 18.08% 73.03% 80.54% -17.08% -167.13% -42.28% -99.61%
Profit (Net Income) Margin		 -24.18% 24.36% 54.50% 54.24% 3.15% -165.01% -37.83% -139.53%
Tax Burden Percent		 98.17% 78.43% 72.83% 68.41% -10.43% 99.89% 101.26% 100.05%
Interest Burden Percent		 51.56% 171.80% 102.46% 98.45% 176.94% 98.84% 88.36% 140.01%
Effective Tax Rate		 0.00% 21.57% 27.17% 31.59% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -20.51% 9.78% 105.06% 200.58% -25.94% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -22.10% 7.06% 102.06% 211.59% -36.50% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 17.27% -5.09% -47.25% -46.67% 27.60% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -3.24% 4.69% 57.81% 153.91% 1.67% -46.75% -18.02% 0.00%
Cash Return on Invested Capital (CROIC)		 -13.65% 52.91% 146.27% 17.22% -187.21% -685.42% 0.00% 0.00%
Operating Return on Assets (OROA)		 -5.58% 3.03% 63.17% 166.73% -5.40% -24.80% -8.26% 0.00%
Return on Assets (ROA)		 -2.82% 4.09% 47.14% 112.28% 1.00% -24.49% -7.39% 0.00%
Return on Common Equity (ROCE)		 -3.24% 4.69% 57.81% 153.91% 1.67% -46.64% -17.90% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -3.43% 4.60% 47.04% 86.54% 1.11% -36.31% -18.08% 0.00%
Net Operating Profit after Tax (NOPAT)		 -952 599 9,850 11,833 -70 -143 -43 -52
NOPAT Margin		 -33.44% 14.18% 53.19% 55.09% -11.96% -116.99% -29.55% -69.64%
Net Nonoperating Expense Percent (NNEP)		 1.59% 2.72% 3.00% -11.01% 10.56% -12.03% -5.12% 0.00%
Return On Investment Capital (ROIC_SIMPLE)		 -4.36% 2.59% 43.80% - - - - -
Cost of Revenue to Revenue		 19.68% 15.71% 17.30% 15.34% 12.30% 16.02% 10.73% 15.13%
SG&A Expenses to Revenue		 19.31% 12.96% 2.78% 1.46% 19.49% 41.90% 20.64% 38.18%
R&D to Revenue		 81.94% 46.69% 8.88% 5.00% 133.73% 208.56% 112.12% 138.80%
Operating Expenses to Revenue		 128.10% 66.22% 9.66% 4.12% 104.79% 250.46% 131.48% 184.35%
Earnings before Interest and Taxes (EBIT)		 -1,360 764 13,525 17,298 -101 -204 -62 -74
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1,052 967 13,657 17,383 -53 -166 -37 -61
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 4.57 10.89 0.60 0.49 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 4.64 12.36 0.74 0.74 0.00
Price to Revenue (P/Rev)		 0.01 0.01 0.00 2.86 30.97 2.74 1.03 2.03
Price to Earnings (P/E)		 0.00 0.02 0.00 5.28 982.61 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 1.42% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 4,046.07% 27,222.64% 18.96% 0.10% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 5.28 34.77 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 2.78 28.96 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 3.44 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 3.45 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 5.05 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 59.32 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 58.80 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.09 0.03 0.05 0.01 0.18 0.15 0.00 0.00
Long-Term Debt to Equity		 0.01 0.01 0.01 0.01 0.17 0.14 0.00 0.00
Financial Leverage		 -0.78 -0.72 -0.46 -0.22 -0.76 -1.13 -1.54 0.00
Leverage Ratio		 1.15 1.15 1.23 1.37 1.67 1.91 2.44 0.00
Compound Leverage Factor		 0.59 1.97 1.26 1.35 2.96 1.89 2.15 0.00
Debt to Total Capital		 8.07% 3.09% 4.60% 1.42% 14.90% 13.07% 0.00% 0.00%
Short-Term Debt to Total Capital		 6.84% 1.99% 3.73% 0.00% 0.56% 0.93% 0.00% 0.00%
Long-Term Debt to Total Capital		 1.24% 1.10% 0.87% 1.42% 14.33% 12.14% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.32% 0.00%
Common Equity to Total Capital		 91.93% 96.91% 95.40% 98.58% 85.10% 86.93% 99.37% 0.00%
Debt to EBITDA		 -1.68 0.74 0.08 0.01 -5.49 -0.50 0.00 0.00
Net Debt to EBITDA		 7.93 -12.61 -1.01 -0.10 22.20 3.01 0.00 0.00
Long-Term Debt to EBITDA		 -0.26 0.26 0.01 0.01 -5.29 -0.47 0.00 0.00
Debt to NOPAT		 -1.85 1.19 0.11 0.02 -4.16 -0.58 0.00 0.00
Net Debt to NOPAT		 8.76 -20.35 -1.40 -0.15 16.82 3.50 0.00 0.00
Long-Term Debt to NOPAT		 -0.28 0.42 0.02 0.02 -4.00 -0.54 0.00 0.00
Altman Z-Score		 1.99 2.38 4.65 14.41 9.86 0.61 0.72 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.23% 0.63% 0.00%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 7.45 9.43 7.43 4.33 2.75 4.05 3.56 0.00
Quick Ratio		 4.45 6.67 7.12 4.04 2.27 3.84 3.41 0.00
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -634 3,240 13,714 1,016 -509 -361 122 0.00
Operating Cash Flow to CapEx		 0.00% 0.00% 3,812.93% 577.73% -16.03% -279.18% -201.66% -274.81%
Free Cash Flow to Firm to Interest Expense		 -22.35 122.56 678.26 2.94 -6.40 -160.64 60.37 0.00
Operating Cash Flow to Interest Expense		 14.44 58.92 662.93 2.92 -0.21 -99.25 -33.28 -1.97
Operating Cash Flow Less CapEx to Interest Expense		 28.59 283.77 645.54 2.41 -1.50 -134.80 -49.79 -2.69
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.12 0.17 0.86 2.07 0.32 0.15 0.20 0.00
Accounts Receivable Turnover		 1.46 0.84 1.71 3.02 5.47 6.96 6.74 0.00
Inventory Turnover		 1.63 1.53 6.17 10.19 1.58 1.97 2.36 0.00
Fixed Asset Turnover		 3.15 5.67 36.43 66.88 3.09 1.35 1.93 0.00
Accounts Payable Turnover		 1.34 2.18 16.04 21.53 0.98 0.55 0.33 0.00
Days Sales Outstanding (DSO)		 249.94 433.25 213.44 120.79 66.77 52.48 54.18 0.00
Days Inventory Outstanding (DIO)		 224.40 238.19 59.18 35.83 230.41 184.87 154.35 0.00
Days Payable Outstanding (DPO)		 271.41 167.77 22.75 16.95 372.79 661.26 1,112.36 0.00
Cash Conversion Cycle (CCC)		 202.92 503.67 249.87 139.68 -75.61 -423.92 -903.83 0.00
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 4,485 4,803 7,444 11,308 491 53 -165 0.00
Invested Capital Turnover		 0.61 0.69 1.98 3.64 2.17 -2.16 -1.77 0.00
Increase / (Decrease) in Invested Capital		 -318 -2,641 -3,864 10,817 438 218 -165 0.00
Enterprise Value (EV)		 -8,313 -12,163 -13,772 59,729 17,060 -165 -320 0.00
Market Capitalization		 27 25 37 61,450 18,245 334 150 150
Book Value per Share		 $84.52 $92.93 $86.93 $0.06 $0.01 $55.38 $30.46 $0.00
Tangible Book Value per Share		 $79.42 $87.58 $85.98 $0.05 $0.01 $45.35 $20.39 $0.00
Total Capital		 21,857 23,110 22,490 13,656 1,969 637 307 0.00
Total Debt		 1,765 713 1,035 194 293 83 0.00 0.00
Total Long-Term Debt		 271 254 195 194 282 77 0.00 0.00
Net Debt		 -8,340 -12,189 -13,809 -1,722 -1,185 -499 -471 0.00
Capital Expenditures (CapEx)		 -401 -5,945 352 174 103 80 33 23
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 8,241 6,868 6,292 11,203 -171 -103 -101 0.00
Debt-free Net Working Capital (DFNWC)		 18,346 19,770 21,136 13,118 1,307 480 369 0.00
Net Working Capital (NWC)		 16,852 19,311 20,296 13,118 1,296 474 369 0.00
Net Nonoperating Expense (NNE)		 -264 -430 -243 184 -89 59 12 52
Net Nonoperating Obligations (NNO)		 -15,608 -17,593 -14,011 -2,153 -1,185 -501 -472 0.00
Total Depreciation and Amortization (D&A)		 308 203 132 85 47 38 25 13
Debt-free, Cash-free Net Working Capital to Revenue		 289.40% 162.56% 33.98% 52.16% -29.07% -84.56% -69.49% 0.00%
Debt-free Net Working Capital to Revenue		 644.24% 467.98% 114.13% 61.08% 221.85% 393.48% 253.06% 0.00%
Net Working Capital to Revenue		 591.77% 457.10% 109.59% 61.08% 219.97% 388.59% 253.06% 0.00%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 ($2.87) $3.87 $38.78 $0.00 $0.06 ($0.85) $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 239.97M 237.73M 240.99M 0.00 241.52B 0.00 0.00 0.00
Adjusted Diluted Earnings per Share		 ($2.87) $3.83 $37.77 $0.00 $0.06 ($0.85) $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 239.97M 237.73M 240.99M 0.00 241.52B 0.00 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.06 ($0.85) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 239.97M 237.73M 240.99M 0.00 241.52B 0.00 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -952 599 9,850 11,833 -70 -143 -43 -52
Normalized NOPAT Margin		 -33.44% 14.18% 53.19% 55.09% -11.96% -116.99% -29.55% -69.64%
Pre Tax Income Margin		 -24.63% 31.06% 74.83% 79.29% -30.23% -165.19% -37.36% -139.46%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 -47.97 28.89 668.93 50.09 -1.27 -90.75 -30.49 -2.30
NOPAT to Interest Expense		 -33.58 22.66 487.18 34.27 -0.89 -63.53 -21.31 -1.61
EBIT Less CapEx to Interest Expense		 -33.82 253.74 651.54 49.59 -2.56 -126.30 -46.99 -3.02
NOPAT Less CapEx to Interest Expense		 -19.43 247.51 469.79 33.76 -2.18 -99.08 -37.81 -2.32
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for BioNTech

No quarterly metrics and ratios for BioNTech are available.

Frequently Asked Questions About BioNTech's Financials

When does BioNTech's financial year end?

According to the most recent income statement we have on file, BioNTech's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has BioNTech's net income changed over the last 7 years?

BioNTech's net income appears to be on an upward trend, with a most recent value of -$688.65 million in 2024, rising from -$103.25 million in 2017. The previous period was $1.03 billion in 2023. See where experts think BioNTech is headed by visiting BioNTech's forecast page.

What is BioNTech's operating income?
BioNTech's total operating income in 2024 was -$1.36 billion, based on the following breakdown:
  • Total Gross Profit: $2.29 billion
  • Total Operating Expenses: $3.65 billion
How has BioNTech revenue changed over the last 7 years?

Over the last 7 years, BioNTech's total revenue changed from $73.99 million in 2017 to $2.85 billion in 2024, a change of 3,748.5%.

How much debt does BioNTech have?

BioNTech's total liabilities were at $3.23 billion at the end of 2024, a 5.7% increase from 2023, and a 630.7% increase since 2018.

How much cash does BioNTech have?

In the past 6 years, BioNTech's cash and equivalents has ranged from $470.96 million in 2018 to $14.84 billion in 2022, and is currently $10.10 billion as of their latest financial filing in 2024.

How has BioNTech's book value per share changed over the last 7 years?

Over the last 7 years, BioNTech's book value per share changed from 0.00 in 2017 to 84.52 in 2024, a change of 8,451.9%.


Related Companies

This page (NASDAQ:BNTX) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Paradigm Press | Sponsored
Banks aren’t ready for this altcoin—are you?
While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...
Crypto 101 Media | Sponsored
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
F1 Engineering Powers This Electric Marine Motor
The future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...
The Tomorrow Investor | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...
Weiss Ratings | Sponsored